Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation INDIANAPOLIS, Jan. 7, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Ventyx Biosciences, Inc. (Nasdaq: VTYX), a San Diego-based clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammatory-mediated diseases, today announced entry into a definitive agreement for Lilly to acquire Ventyx. Ventyx is developing a pipe ...

据华尔街报道， 礼来 正在就以超过10亿美元收购生物技术公司 Ve n t y x Bios c i e n c e s (NAS D AQ:VTYX) 进行后期谈判，美股收盘后股价暴涨57%。 Clinical catalysts represent three potential paths to meaningful value creation in 2025: Late-stage Inflammatory Bowel Disease portfolio provides potential additional source of value: Internally Discovered Clinical-Stage Pipeline Addressing Autoimmune, Inflammatory and Neurodegenerative Diseases with High Unmet Need | 最高: 25.00 | 今开:7.90 | 成交量: 639.75万股 | 换手:8.97% | | --- | --- | --- | --- | | 最低: 7.08 | 昨收:7.8 ...

With strong 1-year returns and upside potential, Ventyx Biosciences, Inc. (NASDAQ:VTYX) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. Analysts Bullish as Ventyx Biosciences (VTYX) Advances Its Clinical and Strategic Initiatives As of December 18, 2025, 90% of analysts are bullish on Ventyx Biosciences, Inc. (NASDAQ:VTYX), setting a median price target of $14.00. This translates into a massive upside potential of 82.05%. Amid this bullish momentum, Ventyx Bioscien ...

Summary of Ventyx Biosciences FY Conference Call Company Overview - **Company**: Ventyx Biosciences (NasdaqGS: VTYX) - **Event**: FY Conference Call on December 03, 2025 Key Points Industry and Product Development - Ventyx is focused on developing VTX2735 for recurrent pericarditis (RP) and has announced a delay in data release to 1Q due to the need for additional patient data and formulation changes [1][2][4] - The company aims to transition to a once-daily (QD) dosing regimen, which is expected to enhance the drug's efficacy profile compared to the current twice-daily (BID) dosing [4][5] - The interim data cut has been postponed to allow for a more comprehensive understanding of the drug's efficacy and mechanism [6][10] Clinical Trial Design and Strategy - The original trial was designed for up to 30 patients, focusing on BID doses, but has been modified to include QD dosing to maximize data extraction [9][10] - The company has received approval to add more trial sites in Canada, the EU, and the UK, which will facilitate a smoother transition to phase 3 trials [6][24][25] - The engagement with regulatory agencies will occur once sufficient data is available, with a typical timeline of 6 to 9 months between phase 2 and phase 3 [23][24] Market Opportunity - The recurrent pericarditis market includes approximately 160,000 patients in the U.S., with 40,000 experiencing multiple recurrences annually [26][27] - ARCALYST, a competing product, is priced over $300,000 per year, providing Ventyx with significant pricing flexibility for its oral therapy [31][36] - The potential for VTX2735 to capture market share is bolstered by its oral administration compared to ARCALYST's infusion method [36] Competitive Landscape - VTX2735 must demonstrate a pain score reduction comparable to ARCALYST to be competitive, with a target pain score of zero or one [16][17] - The company is also exploring the potential for its NLRP3 portfolio in other indications, including cardiovascular diseases, while maintaining a focus on recurrent pericarditis [41][43] Financial and Strategic Position - Ventyx has seen significant stock performance, with a 700% increase over the past year, indicating strong investor interest [52] - The company is positioned to leverage its NLRP3 portfolio, with a focus on maintaining control over its development strategy while exploring partnerships for specific compounds [45][51] Conclusion - Ventyx Biosciences is strategically navigating the clinical development of VTX2735 while positioning itself in a lucrative market for recurrent pericarditis. The company is focused on optimizing its drug profile and expanding its clinical footprint, with a clear path toward phase 3 trials and potential market entry.

Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD dose ranging in preparation for the global Phase 3 development planInterim analysis for the ongoing Phase 2 recurrent pericarditis study to now be presented as part of Ventyx’s R&D Day planned for Q1 2026 SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ve ...

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37th Annual Healthcare Conference in New York. Piper Sandler 37th Annual Healthcare Conference details:Fireside ChatDate ...

Core Viewpoint - Ventyx Biosciences Inc. is experiencing significant stock performance, with a price target increase from Canaccord Genuity following positive Q3 results and promising clinical developments [1][2]. Financial Performance - Ventyx ended Q3 2025 with $192.6 million in cash, a decrease from $209 million in Q2 2025, ensuring operational funding into at least the second half of 2026 [3]. - The company managed to reduce its net loss to $22.8 million, down from $35.2 million in the same period last year, by curtailing R&D and General & Administrative expenses [3]. Clinical Developments - The company has made progress with its VTX3232 therapy, with Phase 2 topline readouts for VTX2735 in recurrent pericarditis expected in Q4 2025 [4]. - Positive Phase 2 Study results for VTX3232 were reported earlier in October, showing significant reductions in cardiovascular risk factors, leading to a 71% increase in share price the following day [5]. Market Sentiment - The stock has rallied 339% year-to-date as of November 20, reflecting strong investor interest and confidence in the company's future prospects [5].

Core Insights - Ventyx Biosciences (VTYX) shares have surged 156% in the past month, driven by positive results from a mid-stage study of its candidate VTX3232 for obesity and cardiovascular risk factors [1][6] Study Results - The phase II study evaluated the safety and tolerability of VTX3232 compared to placebo and in combination with Novo Nordisk's Wegovy [2] - VTX3232 met its primary endpoint, showing safety and tolerability as both a monotherapy and an add-on therapy to Wegovy [3][7] - Significant reductions in inflammation were observed, with VTX3232 monotherapy reducing high-sensitivity C-reactive protein (hsCRP) by 78% in the modified analysis set and 64% in the full analysis set at week 12 [4] Inflammatory Biomarkers - The therapy demonstrated statistically significant reductions in key inflammatory biomarkers, including IL-6, Lp(a), fibrinogen, and ESR, as well as improvements in liver inflammation [5][8] - In combination with Wegovy, VTX3232 further reduced hsCRP and IL-6 levels but did not enhance weight-loss outcomes beyond those achieved with Wegovy alone [7][8] Future Prospects - Ventyx believes that VTX3232 could serve as a compelling adjunct therapy for patients on GLP-1 treatment, with plans to outline next steps for advancing the candidate [9] - The company is also developing VTX3232 for early-stage Parkinson's disease and has other pipeline programs targeting inflammatory bowel disease and recurrent pericarditis [11][14] Market Context - Ventyx's shares have increased 333.8% year-to-date, significantly outperforming the industry growth of 14.9% [6]

Core Insights - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases [3][4] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025 [1][2] Company Overview - Ventyx specializes in oral small molecule therapeutics targeting conditions with high unmet medical needs, leveraging expertise in medicinal chemistry, structural biology, and immunology [3] - The company has a portfolio of NLRP3 inhibitors, including VTX2735 for recurrent pericarditis and VTX3232 for obesity-related cardiovascular risks and Parkinson's disease [4] Upcoming Events - The fireside chat at the Jefferies Global Healthcare Conference is scheduled for November 19, 2025, from 11:00 to 11:25 AM GMT, with a webcast available on the company's website [2]

Core Insights - Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases [3][4] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on November 19, 2025 [1][2] Company Overview - Ventyx specializes in medicinal chemistry, structural biology, and immunology to discover differentiated oral small molecule therapeutics for conditions with high unmet medical needs [3] - The company has extensive experience in clinical development, facilitating the rapid progression of drug candidates through clinical trials [3] Product Pipeline - Ventyx's portfolio includes NLRP3 inhibitors such as VTX2735, which is in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that has completed Phase 2 studies for obesity-related cardiovascular risk factors and Parkinson's disease [4] - The inflammatory bowel disease portfolio features two Phase 2 compounds: tamuzimod (VTX002), a S1P1R modulator, and VTX958, a TYK2 inhibitor [4]